These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 521807)
21. Role of early viral surface antigens in cellular immune response to vaccinia virus. Koszinowski U; Ertl H Eur J Immunol; 1976 Oct; 6(10):679-83. PubMed ID: 65141 [TBL] [Abstract][Full Text] [Related]
22. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. Payne LG J Gen Virol; 1980 Sep; 50(1):89-100. PubMed ID: 7441216 [TBL] [Abstract][Full Text] [Related]
24. An in vitro method for study of human lymphocyte cytotoxicity against mumps-virus-infected target cells. Andersson T; Stejskal V; Harfast B J Immunol; 1975 Jan; 114(1 Pt 1):237-43. PubMed ID: 803527 [TBL] [Abstract][Full Text] [Related]
25. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells. Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991 [TBL] [Abstract][Full Text] [Related]
26. A comparison of the antigens present on the surface of virus released artificially from chick cells infected with vaccinia virus, and cowpox virus and its white pock mutant. Baxby D J Hyg (Lond); 1972 Jun; 70(2):353-65. PubMed ID: 4624399 [TBL] [Abstract][Full Text] [Related]
28. Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. Stitz L; Schmitz C; Binder D; Zinkernagel R; Paoletti E; Becht H J Gen Virol; 1990 May; 71 ( Pt 5)():1169-79. PubMed ID: 1693165 [TBL] [Abstract][Full Text] [Related]
29. Differences between extracellular and intracellular forms of poxvirus and their implications. Boulter EA; Appleyard G Prog Med Virol; 1973; 16():86-108. PubMed ID: 4356899 [No Abstract] [Full Text] [Related]
30. Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies. Czerny CP; Mahnel H J Gen Virol; 1990 Oct; 71 ( Pt 10)():2341-52. PubMed ID: 1700065 [TBL] [Abstract][Full Text] [Related]
31. Differentiation of variola, monkeypox, and vaccinia antisera by radioimmunoassay. Hutchinson HD; Ziegler DW; Wells DE; Nakano JH Bull World Health Organ; 1977; 55(5):613-23. PubMed ID: 201390 [TBL] [Abstract][Full Text] [Related]
32. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Aldaz-Carroll L; Whitbeck JC; Ponce de Leon M; Lou H; Pannell LK; Lebowitz J; Fogg C; White CL; Moss B; Cohen GH; Eisenberg RJ Virology; 2005 Oct; 341(1):59-71. PubMed ID: 16083934 [TBL] [Abstract][Full Text] [Related]
34. Soluble antigens of vaccinia virus. Note I. Chemical and biological properties. Immunogenic capacity. Mihăilescu R; Olinescu A; Popa L; Stavri H; Iancu L Arch Roum Pathol Exp Microbiol; 1987; 46(1):35-46. PubMed ID: 2449147 [No Abstract] [Full Text] [Related]
35. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera. Leddy JP; Simons RL; Douglas RG J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701 [TBL] [Abstract][Full Text] [Related]